CLARSON GOFF (F3D) LIMITED

Financial Health Assessment: CLARSON GOFF (F3D) LIMITED

1. Financial Health Score: F (Terminal / Deceased)

Explanation: The company has ceased all trading activities and is in the process of being formally wound up. The balance sheet has been scrubbed completely clean, leaving zero assets, zero liabilities, and zero net worth. This is not a company suffering from a curable illness; it is the financial equivalent of a patient who has passed away and is awaiting the final legal death certificate.

2. Key Vital Signs

• Pulse (Cash Flow): Flatlined. As of 31 December 2024, cash at bank stands at £0, down from a negligible £153 in 2023. There is no financial circulation remaining.
• Blood Pressure (Working Capital): Zero. Current assets and current liabilities both sit at £0. The company has no short-term obligations and no short-term resources, indicating a complete cessation of business operations.
• Body Mass (Total Assets): Emaciated. Total assets have dropped to £0. This is a stark contrast to 2014, when the company had a healthy mass of £1.13 million in assets.
• Neurological Function (Trading Status): Non-responsive. The latest filed accounts explicitly state: "The company has ceased to trade and therefore the directors intend to wind up the company."

3. Symptoms Analysis & Diagnosis

Symptoms Analysis: Looking at the medical history, this company was once relatively healthy. In 2014, it had over £1.1 million in assets and nearly £1 million in shareholder equity. However, over the subsequent decade, the business experienced severe atrophy. By 2021, assets had withered to just £1,520, and the company was surviving on life support via intercompany loans from its parent, F3Group Limited.

In 2024, we see a sudden and drastic "purge." The intercompany debtor balance of £550 and the intercompany creditor balance of £2,250 were both wiped to zero. Simultaneously, the accumulated profit and loss deficit of £2,257,900 was exactly offset by the called-up share capital of £2,257,900, resulting in a net equity of £0.

Diagnosis: The patient is clinically deceased. The 2024 financial maneuvering is a classic "balance sheet wash." By offsetting the massive accumulated losses against the share capital and clearing intercompany balances, the directors are tidying up the financial body before burial. The company is a shell with no operational capacity, no cash, and no net value.

4. Prognosis

Future Outlook: Inevitable dissolution. The directors have stated they intend to wind up the company within 12 months of the accounts' approval date. The company status is already flagged as dissolved. There is no future financial outlook for this entity; it will be struck off the public register and cease to exist as a legal person.

5. Recommendations

Because the company is effectively a corporate cadaver, recommendations for financial rehabilitation are moot. However, for the "coroners" (the directors and parent company) managing the final arrangements, the following administrative steps are advised: * Final Statutory Compliance: Ensure all remaining tax returns (Corporation Tax) are filed with HMRC and any final notices are closed out to prevent personal liability for the directors. * Records Retention: Ensure all company books and records are securely archived for the statutory period (usually 6 years from the end of the company's financial year) in case of any post-dissolution inquiries. * Parent Group Review: The parent company, F3Group Limited, should ensure that the write-off of intercompany balances has been properly accounted for in its own consolidated financial statements.